I mean, Clinical depression is a tough indication for Biotech to tackle – particularly when facing off a ’55-year old’ generic (amitriptyline). But e-Therapeutics in Oxford (UK) has more to offer in its pipeline, despite this phase IIb failure in Glasgow.
The trial’s aims were to determine whether ETS6103 was an antidepressant capable of treating the patients for whom first-line selective serotonin re-uptake inhibitor (SSRI) treatments had not worked.
It was hoped this small-molecule could improve the consistency of treatment for Major Depressive Disorder (also known as clinical depression). The plan was that this candidate would have more benign side effects and a better tolerance profile than tricyclic antidepressants like amitriptyline (also a popular painkiller on the market).
Having already produced encouraging data in a small phase IIa study, benefits in speed of onset and in the effect on depression scores were demonstrated between the beginning and end of the trial over amitriptyline, as well as the expected benefits in side effects and tolerance.